Patritumab deruxtecan, produced by Daiichi Sankyo, in Phase 2 clinical trial is a topoisomerase I inhibitor conjugated to a IgG1 antibody that targets HER3+ breast cancer as well as EGFR-mutated non-small cell lung cancer [112]. Here, ERBB3 is linked to breast carcinoma.